中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

17656 records (took 0.031 seconds)

    PHOSPHODIESTERASE INHIBITORS FOR THE MITIGATION OF FRAGILE X SYNDROME SYMPTOMS
    71.
    发明申请
    PHOSPHODIESTERASE INHIBITORS FOR THE MITIGATION OF FRAGILE X SYNDROME SYMPTOMS 审中-公开

    公开(公告)号：WO2023279193A2

    公开(公告)日：2023-01-12

    申请号：PCT/CA2022/000034

    申请日：2022-07-08

    Applicant: THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY

    Inventor： BOWIE, Derek

    IPC: A61K31/519 ,  A61K31/44 ,  A61P25/00 ,  C07D213/16 ,  C07D487/04 ,  G01N33/50 ,  A61K31/00

    Abstract: The present disclosure concerns agents and therapeutic methods of mitigating at least one symptom of Fragile X syndrome (FXS) GRIN disorder, SynGAPI intellectual disability or Phelan-McDermid syndrome. The agents are inhibitors of one or more phosphodiesterase capable of hydrolyzing cGMP and optionally cAMP. In some embodiments, the agents can be inhibitors of a phosphodiesterase 1, 2, 5 or 10. The present disclosure also concerns a screening method for identifying test agents capable of mitigating at least one symptom of FXS. The screening methods determines that the test agent (or the combination of test agents) is useful when it is capable of increasing the activity of the neuronal nitric oxide synthase. Preferably, a mGluR5 blocking agent is combined with the phosphodiesterase inhibitors for the treatments described herein.

    METHODS FOR TREATING DEPRESSIVE STATES
    73.
    发明申请
    METHODS FOR TREATING DEPRESSIVE STATES 审中-公开

    公开(公告)号：WO2023278824A1

    公开(公告)日：2023-01-05

    申请号：PCT/US2022/035919

    申请日：2022-07-01

    Applicant: BIOXCEL THERAPEUTICS, INC. ,  RISINGER, Robert ,  BEASLEY, Charles

    Inventor： DE VIVO, Michael ,  YOCCA, Frank D.

    IPC: A61P25/22 ,  A61K31/4174 ,  A61P25/00 ,  C07D405/00

    Abstract: The present disclosure relates to method of treating or preventing depression in a human subject having Major Depressive Disorder or a Major Depressive Episode, the method comprising (a) an induction phase, comprising administering to the subject a therapeutic amount of dexmedetomidine or a pharmaceutically acceptable salt thereof in combination with a therapeutic amount of a selective serotonin reuptake inhibitor (SSRI)/serotonin norepinephrine reuptake inhibitors (SNRI) from about 1 day to about 28 days, followed by (b) a maintenance phase comprising administering to the subject a therapeutic amount of the SSRI/SNRI.

    一种维生素C加锌缓控释片及其制备方法
    77.
    发明申请
    一种维生素C加锌缓控释片及其制备方法 审中-公开

    公开(公告)号：WO2023272694A1

    公开(公告)日：2023-01-05

    申请号：PCT/CN2021/104052

    申请日：2021-07-01

    Applicant: 思瑰瑞保健食品有限公司

    Inventor： 贾毅

    IPC: A61K33/30 ,  A61K9/36 ,  A61K9/30 ,  A61K47/38 ,  A61K47/44 ,  A61K47/12 ,  A61P37/04 ,  A61P25/00 ,  A61P15/00 ,  A61P31/12 ,  A61K31/375

    Abstract: 本发明涉及维生素C缓释技术领域，具体涉及一种维生素C加锌缓控释片及其制备方法。由片状药芯与缓释包衣组成，片状药芯包括原料是维生素C 10～15份，含锌离子物质10～15份，水余量；缓释包衣包括原料是主成膜剂20～80份，预胶化淀粉10～20份，增韧剂5～15份，抗粘连剂3～8份，增塑剂2～6份，着色剂1～5份，助剂1～5份，乙醇余量。维生素C与锌混合，在补充维生素C同时，补充微量元素锌，有利于人体内多种酶反应的顺利进行，具有很好的韧性、耐磨性，通过缓控释包衣实现长效匀速释放，锌的吸收要细胞膜上载体蛋白进行主动转运，更长的释放时间，可避免短期载体饱和，更长释放时间和载体转运时间，提高吸收利用率。

Patent Agency Ranking